藥明生物(02269.HK)在公開市場斥資39.202億港元購回4505.8萬股
格隆匯1月6日丨藥明生物(02269.HK)發佈公吿,2021年12月16日至2022年1月5日,根據購回授權,公司分別按最高價每股94.35港元及最低價每股78.45港元於聯交所購回合共4505.8萬股股份。已付股份購回的購買價合共約39.202億港元。根據股份購回所購回的股份佔緊接股份購回前公司已發行股份總數約1.06%。公司隨後將會註銷所購回的股份。
公司的財政狀況穩健。公司認為,股份購回及其後註銷所購回的股份可提高股份價值,從而改善公司股東的回報。此外,股份購回反映公司對其業務發展及強勁增長前景充滿信心。公司相信股份購回符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.